TY - JOUR T1 - Efficacy of face masks, neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols JF - medRxiv DO - 10.1101/2020.10.05.20207241 SP - 2020.10.05.20207241 AU - William G. Lindsley AU - Francoise M. Blachere AU - Brandon F. Law AU - Donald H. Beezhold AU - John D. Noti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/07/2020.10.05.20207241.abstract N2 - Face masks are recommended to reduce community transmission of SARS-CoV-2. One of the primary benefits of face masks and other coverings is as source control devices to reduce the expulsion of respiratory aerosols during coughing, breathing, and speaking. Face shields have been proposed as an alternative to face masks, but information about face shields as source control devices is limited. We used a cough aerosol simulator with a headform to propel small aerosol particles (0 to 7 µm) into different face coverings. An N95 respirator blocked 99% of the cough aerosol, a procedure mask blocked 59%, a 3-ply cloth face mask blocked 51%, and a polyester neck gaiter blocked 47% as a single layer and 60% when folded into a double layer. In contrast, the face shield blocked 2% of the cough aerosol. Our results suggest that face masks and neck gaiters are preferable to face shields as source control devices for cough aerosols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute for Occupational Safety and Health (NIOSH), US Centers for Disease Control and Prevention (CDC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExperimental data is available upon request. ER -